- Home
- CIFR vs AXSM Comparison
CIFR vs AXSM Comparison
Compare CIFR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | AXSM |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CIFR | AXSM |
|---|---|---|
| Price | $16.19 | $153.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | $25.60 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 39.8M | 471.7K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $206,454,000.00 | ★ $561,263,000.00 |
| Revenue This Year | $69.76 | $66.20 |
| Revenue Next Year | $57.25 | $57.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 35.41 | ★ 65.83 |
| 52 Week Low | $1.86 | $75.56 |
| 52 Week High | $25.52 | $152.94 |
Technical Indicators
Market Signals| Indicator | CIFR | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 63.09 |
| Support Level | $13.67 | $145.07 |
| Resistance Level | $16.00 | $149.13 |
| Average True Range (ATR) | 1.70 | 4.48 |
| MACD | -0.39 | -0.41 |
| Stochastic Oscillator | 35.29 | 88.36 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.